Failure to prevent multiple simultaneous enrollment in clinical trials and inaccuracies in subjects’ medical histories have become a serious problem in the clinical research world.
Garden City, NY (PRWEB) November 25, 2013
The Verified Clinical Trials registry is effective in halting the professional research subject from enrolling in multiple clinical trials simultaneously – a situation known as dual enrollment in clinical trials. Many of the world's largest and most relevant pharmaceutical and clinical research companies collaborate to stop dual enrollment.
Major pharmaceutical companies have consistently turned to Verified Clinical Trials to improve safety and data quality in their clinical trials. Most recently, Verified Clinical Trials will soon add over 800 North American sites to their database for a large scale phase 3 respiratory trial.
Mitchell Efros MD FACS President and CEO of Verified Clinical Trials stated, "We are thrilled with the uptake of the Verified Clinical Trials system in both early and late phase trials."
Failure to prevent multiple simultaneous enrollment in clinical trials and inaccuracies in subjects’ medical histories have become a serious problem in the clinical research world. Study volunteers interested in free care or compensation may present inaccurate information in order to gain entry to clinical trials, and some may jump from one study to another without waiting for enough time to lapse between treatments. This type of research volunteer places everyone at risk including the drug manufacturer, the research site, and most importantly, themselves, potentially jeopardizing their health. Furthermore, this may compromise data quality.
About Verified Clinical Trials
Verified Clinical Trials, (VCT) (http://www.verifiedclinicaltrials.com) the world's leader in the field of clinical trial database registries, proactively improves research subject safety and data quality in clinical research trials by halting dual enrollment in clinical trials. With a web-based solution designed to enhance the quality of both early and late phase trials, VCT has the scalability to reach all sites nationally and globally and is HIPAA- and 21 CFR part 11-compliant.